Activation of the PI3K/AKT/mTOR pathway has long been associated with resistance to multiple targeted therapies across multiple tumor types [8,9,10], leading to the evaluation of combination therapies integrating inhibitors of this pathway. Here, AKT1 is linked to neoplasm.